Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDC2503
- Development stage
- Preclinical
- Lead developer
- Prestige Biopharma Innovative Discovery Centre
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IDC2503 is a preclinical-stage monoclonal antibody biosimilar being developed by Prestige Biopharma (PBK). It is designed as a biosimilar to atezolizumab (marketed as Tecentriq), a humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). By inhibiting the interaction between PD-L1 and its receptors, PD-1 and B7.1, IDC2503 acts as an immune checkpoint inhibitor, preventing the suppression of T-cell-mediated immune responses against tumor cells. The drug is currently in preclinical development for the treatment of non-small cell lung cancer (NSCLC) and urothelial carcinoma, aiming to provide a therapeutic profile similar to the reference product.
- Other names
- atezolizumab biosimilar
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on IDC2503.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDC2503.